Abstract
Objective: To evaluate the efficacy and safety of live combined Bifidobacterium, Lactobacillus and Enterococcus capsules in treatment of irritable bowel syndrome. Methods: Eighty-five patients [male 32, female 53; age (45.31±11.72) years] were given live combined Bifidobacterium, Lactobacillus and Enterococcus capsules 1260 mg/d t.i.d.×4 weeks. Syndrome scales were used to evaluate the efficacy in gastrointestinal syndrome. Fecal flora was also measured before and after the treatment. Six bacteria were cultured and the colony forming units were counted in stool. SPSS was used for data analysis. Results: Seventy-four patients finished the follow-up. No side-effect was found. For treatment of irritable bowel syndrome, the effective rate of live combined Bifidobacterium, Lactobacillus and Enterococcus capsules was 56.8% in the second week, 74.3% in the fourth week and 73.0% in the sixth week. Single symptom was improved, especially in abdominal pain and stool character. The probiotica containing live combined Bifidobacterium, Lactobacillus and Enterococcus could increase bifidobacterium count (P<0.01) and lactobacillus count (P<0.05); decrease bacteroides count (P<0.05) and enterococci count (P<0.01); No obvious changes were observed in clostridium difficile colonitis and enterobacteriaceae (P>0.05). Conclusion: The result of the study indicated that the administration of live combined Bifidobacterium, Lactobacillus and Enterococcus improved the symptom of irritable bowel syndrome and that there was a gradual increase of this effect. Thereafter conditions remained stable for 2 weeks. That improvement may be associated with alterations in gastrointestinal flora.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Balsari, A., Ceccarelli, A., Dubini, F., Fesce, E., Poli, G., 1982. The fecal microbial population in the irritable bowel syndrome. Microbiology, 5(3):185–194.
Brigidi, P., Vitali, B., Swennen, E., Bazzocchi, G., Matteuzzi, D., 2001. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res. Microbiol., 152(8):735–741. [doi:10.1016/S0923-2508(01)01254-2]
Drossman, D.A., Sandler, R.S., McKee, D.C., Lovitz, A.J., 1982. Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology, 83(3):529–534.
Everhart, J.E., Renault, P.F., 1991. Irritable bowel syndrome in office-based practice in the Unite States. Gastroenterology, 100(4):998–1005.
Kajander, K., Hatakka, K., Poussa, T., Farkkila, M., Korpela, R., 2005. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment. Pharmacol. Ther., 22(5):387–394. [doi:10.1111/j.1365-2036.2005.02579.x]
King, T.S., Elia, M., Hunter, J.O., 1998. Abnormal colonic fermentation in irritable bowel syndrome. Lancet, 352(9135):1187–1189. [doi:10.1016/S0140-6736(98)02146-1]
Koide, A., Yamaguchi, T., Odaka, T., Koyama, H., Tsuyuguchi, T., Kitahara, H., Ohto, M., Saisho, H., 2000. Quantitative analysis of bowel gas using plain abdominal radiograph in patients with irritable bowel syndrome. Am. J. Gastroenterol., 95(7):1735–1741. [doi:10.1111/j.1572-0241.2000.02189.x]
Maxwell, P.R., Mendall, M.A., Kumar, D., 1997. Irritable bowel syndrome. Lancet, 350(9092):1691–1695. [doi:10.1016/S0140-6736(97)05276-8]
Nayak, A.K., Karnad, D.R., Abraham, P., Mistry, F.P., 1997. Metronidazole relieves symptoms in irritable bowel syndrome: the confusion with so-called “chronic amebiasis”. Indian J. Gastroenterol., 16(4):137–139.
Nobaek, S., Johansson, M.L., Molin, G., Ahrne, S., Jeppsson, B., 2000. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am. J. Gastroenterol., 95(5):1231–1238. [doi:10.1111/j.1572-0241.2000.02015.x]
O’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O’sullivan, G.C., Kiely, B., Collins, J.K., Shanahan, F., Quigley, E.M., 2005. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology, 128(3):541–551. [doi:10.1053/j.gastro.2004.11.050]
Pimentel, M., Chow, E.J., Lin, H.C., 2000. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am. J. Gastroenterol., 95(12):3503–3506. [doi:10.1111/j.1572-0241.2000.03368.x]
Pimentel, M., Chow, E.J., Lin, H.C., 2003. Normalication of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized placebo-controlled study. Am. J. Gastroenterol., 98(2):412–419. [doi:10.1111/j.1572-0241.2003.07234.x]
Rodriguez, L.A., Ruigomez, A., 1999. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ, 318(7183):565–566.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fan, Yj., Chen, Sj., Yu, Yc. et al. A probiotic treatment containing Lactobacillus, Bifidobacterium and Enterococcus improves IBS symptoms in an open label trial. J. Zhejiang Univ. - Sci. B 7, 987–991 (2006). https://doi.org/10.1631/jzus.2006.B0987
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1631/jzus.2006.B0987